IL-NIELSENIQ/FOXINTEL
8.12.2021 13:03:07 CET | Business Wire | Press release
The shopper journey continually evolves as consumers have more control over what they do, see, and hear. That means the tools used to measure and analyze sales, market share and consumer behavior must also change. In an environment that continues to experience seismic shifts, measuring when, where and how consumers are buying is imperative. This allows fast-moving consumer goods (FMCG) manufacturers and retailers to anticipate trends and react faster to consumers’ needs and expectations.
Although the fastest growing channel in Western Europe and North America is online, e-commerce measurement tools are largely fragmented. Users must combine data from multiple sources to get a full picture of the market. NielsenIQ is transforming the FMCG and retail industry with its innovative solutions and precise insights, which offer an integrated, accurate, complete, and more granular view of the offline and online marketplace—making it easier to analyze trends across channels.
Our latest acquisition, Foxintelligence, will strengthen our offering globally.
Foxintelligence is the largest e-commerce measurement and consumer data analytics company in Europe. It operates Europe’s largest GDPR-compliant consumer panel, boasting over 600,000 active online buyers in France, Germany, Italy, Spain, and the United Kingdom and will be able to expand its coverage and offering to additional markets as a NielsenIQ-powered company.
Eight months after becoming a standalone company, NielsenIQ has made several key acquisitions and significantly increased its investments to accelerate its product delivery and build comprehensive solutions, transforming the measurement and analytics solutions available to the rapidly changing FMCG and retail industry.
“Our goal is to transform the way we operate and serve our customers, helping them to accelerate growth. The investments we have made so far are building the foundation for NielsenIQ's transformation and bringing key talent in-house to address some of the most critical issues our customers face today and will face in the future,” said Lorena Elizondo, Chief Strategy Officer, NielsenIQ.
“NielsenIQ’s ambition is to approach e-commerce holistically. Foxintelligence is instrumental in this strategy, expanding the footprint of our unmatched retail measurement solution. They uncover the online blind spots like marketplaces, category specialists, direct-to-consumer, quick-commerce and last milers, among others, providing full-market coverage,” said Clément Colin, Head of International E-commerce Measurement, NielsenIQ.
Foxintelligence gathers and anonymizes e-receipts to create detailed, comprehensive, and proprietary transaction data. This data is the cornerstone of market intelligence in today’s digital consumption age, and NielsenIQ will propel it forward.
“We are extremely proud and happy to join the NielsenIQ family. We have been working for over a year on common themes to bring ever more value to our clients and we will now provide them a more comprehensive and integrated vision of the online and offline marketplace,” said Edouard Nattée, CEO and Founder of Foxintelligence.
The acquisition of Foxintelligence marks the latest bold step NielsenIQ is taking in providing groundbreaking, comprehensive e-commerce data. In September 2021, NielsenIQ acquired Rakuten Intelligence and Data Impact to enhance its e-commerce solution portfolio and scale it globally.
About NielsenIQ
NielsenIQ is the leader in providing the most complete, unbiased view of consumer behavior, globally. Powered by a groundbreaking consumer data platform and fueled by rich analytic capabilities, NielsenIQ enables bold, confident decision-making for the world’s leading consumer goods companies and retailers.
Using comprehensive data sets and measuring all transactions equally, NielsenIQ gives clients a forward-looking view into consumer behavior in order to optimize performance across all retail platforms. Our open philosophy on data integration enables the most influential consumer data sets on the planet. NielsenIQ delivers the complete truth.
NielsenIQ, an Advent International portfolio company, has operations in nearly 100 markets, covering more than 90% of the world’s population. For more information, visit NielsenIQ.com .
About Foxintelligence
Foxintelligence mission is to empower decision-makers with data to improve the way societies and companies work. The company delivers the best insights on the latest European ecommerce trends, by unlocking intelligence from hundreds of merchants and thousands of brands e-receipts. By doing so, Foxintelligence collects commercial information about ecommerce from e-mails (e.g., e-receipts): thanks to their proprietary technology, Foxintelligence can structure this vast amount of data to generate unseen insights on the market and make them available on their SaaS platform: Foxapp.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005244/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
